NCT02136316

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy Subjects

A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Oral Multiple Doses of ASP7962 in Healthy Male and Female Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Astellas Pharma Europe B.V. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety and tolerability as well as the pharmacokinetics of increasing oral multiple doses of ASP7962 in healthy young male and female subjects.

Detailed description

Subjects will be admitted to the clinical unit and will stay residential for a total of 20 days/19 nights, to be discharged from the clinical unit on day 19.

Conditions

• Healthy Volunteers
• Pharmacokinetics of ASP7962

Interventions

Type	Name	Description
DRUG	ASP7962	Oral
DRUG	Placebo	Oral

Timeline

• Start date: 2014-05-01
• Primary completion: 2015-11-01
• Completion: 2015-11-01
• First posted: 2014-05-13
• Last updated: 2015-12-15

Locations

1 site across 1 country: United Kingdom